Citations

Clear

3138 citation(s) found for "Smith, AM".

Author response: Risk factors affecting polygenic score performance across diverse cohorts
Hui, D. , Dudek, Scott , Walunas, Theresa L. , Wei, Wei‐Qi, Tiwari, Hemant K., Khan, Atlas , Limdi, Nita A. , Feng, QiPing , Karlson, Elizabeth W. , Ritchie, Marylyn D. , Feng, Qiping , Walunas, Theresa L , Hui, Daniel, Kiryluk, Krzysztof , Kullo, Iftikhar J. , Peterson, Josh F. , Chung, Wendy K. , Davis, Brittney H. , Kottyan, Leah C. , Puckelwartz, Megan J. , Weng, Chunhua , Smith, Johanna L. , Jarvik, Gail P.

Mayo Clinic

No container title available | January 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.88149.3.sa2 Get It

Risk factors affecting polygenic score performance across diverse cohorts
Hui, Daniel , Dudek, Scott , Walunas, Theresa L. , Kullo, Iftikhar, Wei, Wei‐Qi, Tiwari, Hemant K., Limdi, Nita A. , Puckelwartz, Megan J, Karlson, Elizabeth W. , BioBank, Penn Medicine, Jarvik, Gail P., Ritchie, Marylyn D. , Walunas, Theresa L , Kiryluk, Krzysztof , Kullo, Iftikhar J. , Peterson, Josh F. , Chung, Wendy K. , Davis, Brittney H. , Khan, Atlas , Kottyan, Leah C. , Feng, QiPing , Puckelwartz, Megan J. , Weng, Chunhua , Smith, Johanna L. , BioBank, Penn Medicine, Jarvik, Gail P

Mayo Clinic

eLife | January 24, 2025 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.88149.3 Get It

Apart from ancestry, personal or environmental covariates may contribute to differences in polygenic score (PGS) performance. We analyzed the effects of covariate stratification and interaction on body mass index (BMI) PGS (PGS BMI ) across four cohorts of European (N = 491,111) and African (N = 21,612) ancestry. Stratifying on binary covariates and quintiles for continuous covariates, 18/62 covariates had significant and replicable R 2 differences among strata. Covariates with the largest differences included age, sex, blood lipids, physical activity, and alcohol consumption, with R 2 being nearly double between best- and worst-performing quintiles for certain covariates. Twenty-eight covariates had significant PGS BMI –covariate interaction effects, modifying PGS BMI effects by nearly 20% per standard deviation change. We observed overlap between covariates that had significant R 2 differences among strata and interaction effects – across all covariates, their main effects on BMI were correlated with their maximum R 2 differences and interaction effects (0.56 and 0.58, respectively), suggesting high-PGS BMI individuals have highest R 2 and increase in PGS effect. Using quantile regression, we show the effect of PGS BMI increases as BMI itself increases, and that these differences in effects are directly related to differences in R 2 when stratifying by different covariates. Given significant and replicable evidence for context-specific PGS BMI performance and effects, we investigated ways to increase model performance taking into account nonlinear effects. Machine learning models (neural networks) increased relative model R 2 (mean 23%) across datasets. Finally, creating PGS BMI directly from GxAge genome-wide association studies effects increased relative R 2 by 7.8%. These results demonstrate that certain covariates, especially those most associated with BMI, significantly affect both PGS BMI performance and effects across diverse cohorts and ancestries, and we provide avenues to improve model performance that consider these effects.
Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae
Thakolwiboon, Smathorn , Gilligan, Michael , Orozco, Emma, Dubey, Divyanshu , López‐Chiriboga, A. Sebastian , Valencia-Sánchez, Cristina , Zalewski, Nicholas L. , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Dubey, Divyanshu , Pittock, S J , Flanagan, E P , Valencia Sanchez, Cristina , Zekeridou, Anastasia , McKeon, Andrew , Dubey, Divyanshu , Gilligan, Michael , Thakolwiboon, Smathorn , Britton, Jeffrey W. , Flanagan, Eoin P. , Smith, Kelsey M. , McKeon, Andrew

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | January 20, 2025 | Volume: 96 | Issue: 8 | Pages: 736-743

10.1136/jnnp-2024-334957 | PMID 39832911 Get It

Background Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited. Methods This retrospective observational study investigated outcomes in 182 patients who met the 2016 criteria for definite AE. Recovery data were available in 172 patients. Follow-up data at ≥24 months post-attack were available for 119. Recovery trajectory, residual symptoms, outcome predictors and causes of post-AE death were assessed. Results Of 172 patients, 138 (80%) achieved good recovery (modified Rankin Scale (mRS) ≤2) with a median recovery time of 4 months (95% CI: 2 to 6 months). Recovery varied by associated neural antibody, with the best recovery observed in leucine-rich glioma-inactivated 1 (97% good recovery, median recovery time 0 (0 to 2) months). Paraneoplastic AE (p=0.007), severe attacks (eg, mRS ≥4 at attack, p=0.007) and cerebrospinal fluid pleocytosis (p=0.005) were associated with a lower likelihood of good recovery, while seizure presentation (p=0.026) was associated with better recovery. Despite good recovery, several residual symptoms persisted ≥24 months post-AE, including cognitive deficits (53%), seizures (26%), depression (23%), sleep disorders (25%), brainstem/cerebellar symptoms (13%), other movement disorders (14%) and autonomic symptoms (12%). Predictors of long-term sequelae included disabling cognitive deficit at onset and delayed immunotherapy for post AE-dementia, and medial temporal atrophy as well as escalation to cyclophosphamide therapy for both drug-resistant epilepsy and chronic depression. Of 182 patients, 20 (11%) died; the most common cause of death was progression of AE (6/20 (30%)). Conclusion While the majority of patients achieved functional independence after AE, several residual symptoms persisted. Several clinical and paraclinical features were associated with long-term sequelae.
Correlating autonomic physiology with symptoms of autonomic dysreflexia after spinal cord injury
Higano, Jennifer Dens , Burns, Kathryn , Smith, Geoffrey , Solinsky, Ryan , Dens Higano, Jennifer , Solinsky, Ryan

Mayo Clinic

PM&R | January 16, 2025 | Volume: 17 | Issue: 5 | Pages: 478-484

10.1002/pmrj.13295 | PMID 39817508 Get It

AbstractBackgroundIndividuals with spinal cord injury (SCI) commonly have autonomic dysreflexia (AD) with increased sympathetic activity. After SCI, individuals have decreased baroreflex sensitivity and increased vascular responsiveness.ObjectiveTo evaluate the relationship between baroreflex and blood vessel sensitivity with AD symptoms.DesignCase control.SettingTertiary academic center.Patients14 individuals with SCI, 17 matched uninjured controls.InterventionsAll participants quantified AD symptoms using the Autonomic Dysfunction Following SCI (ADFSCI)‐AD survey. Participants received three intravenous phenylephrine boluses, reproducibly increasing systolic blood pressure (SBP) 15–40 mmHg. Continuous heart rate (R‐R interval, ECG), beat‐to‐beat blood pressures (Finapres), and popliteal artery flow velocity were recorded. Vascular responsiveness (α1 adrenoreceptor sensitivity) and heart rate responsiveness to increased SBP (baroreflex sensitivity) were calculated.Main Outcome MeasuresBaroreflex sensitivity after increased SBP; Vascular responsiveness through quantified mean arterial pressure (MAP) 2‐minute area under the curve and change in vascular resistance.ResultsSCI and control cohorts were well matched with mean age 31.9 and 29.6 years (p = .41); 21.4% and 17.6% female, respectively. Baseline MAP (p = .83) and R‐R interval (p = .39) were similar. ADFSCI‐AD scores were higher following SCI (27.9 ± 22.9 vs. 4.2 ± 2.9 in controls, p = .002). To quantify SBP response, MAP area under the curve was normalized to dose/body weight. Individuals with SCI had significantly larger responses (0.26 ± 0.19 mmHg*s/kg*μg) than controls (0.06 ± 0.06 mmHg*s/kg*μg, p = .002). Similarly, leg vascular resistance increased after SCI (24% vs. 6% to a normalized dose, p = .007). Baroreflex sensitivity was significantly lower after SCI (15.0 ± 8.3 vs. 23.7 ± 9.3 ms/mmHg, p = .01). ADFSCI‐AD subscore had no meaningful correlation with vascular responsiveness (R2 = 0.008) or baroreflex sensitivity (R2 = 0.092) after SCI.ConclusionsAlthough this confirms smaller previous studies suggesting increased α1 adrenoreceptor sensitivity and lower baroreflex sensitivity in individuals with SCI, contrary to our hypothesis these differences lacked correlation to increased symptoms of AD. Further research into physiologic mechanisms is needed to explain why some individuals with SCI develop symptoms.
Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data
Abiri, Arash , Nguyen, Theodore V. , Chen, Haidee , Krippaehne, Elise , Rahman, Arifeen S. , Roozdar, Pooya, Rosvall, Brandon R., Sabbaj, Michael , Adappa, Nithin D. , Chang, Eugene H., Chang, Michael T. , Kohanski, Michael A. , Hwang, Peter H. , Lee, Jivianne T. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Krippaehne, Elise , Rahman, Arifeen S , Beswick, Daniel , Chang, Michael T , Choby, Garret , Eide, Jacob G. , Douglas, Jennifer E , Hwang, Peter H , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Kuan, Edward C , Nguyen, Theodore V , Lerner, David K. , Workman, Alan D. , Wu, Shannon S. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H., Choby, Garret , Geltzeiler, Mathew , Le, Christopher H. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | January 15, 2025 | Volume: 15 | Issue: 6 | Pages: 585-593

10.1002/alr.23531 | PMID 39811891 Get It

ABSTRACTBackgroundOlfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of the anterior cranial fossa. Surgery can be performed with unilateral or bilateral resection depending on extent of involvement; however, there are currently no studies comparing outcomes between the two.MethodsProspective and retrospective data on primary ONB patients were collected from a multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts with similar baseline characteristics. Cox proportional hazards and Kaplan Meier analyses assessed overall survival (OS). Logistic regression assessed associations between extent of resection (unilateral versus bilateral) and tumor recurrence or postoperative cerebrospinal fluid (CSF) leak.ResultsA total of 187 ONB patients (47.6% female) with an average age of 53.6 ± 15.1 years were analyzed. Most tumors were unilateral (81.3%) and predominantly Kadish C (58.3%) or Hyams II (55.8%). Overall, 56.7% of patients underwent bilateral resection. Fifty‐four patients experienced tumor recurrence and nine had postoperative CSF leaks. Following PSM (n = 45/group), extent of resection was not associated with mortality (hazard ratio [HR] 1.73; p = 0.407) or OS (p = 0.400). There was no association between extent of resection and recurrence (odds ratio [OR] 0.90; p = 0.814) or postoperative CSF leak (OR 1.54; p = 0.647).ConclusionsFor ONB tumors where unilateral resection may be feasible and oncologically sound, the decision for unilateral versus bilateral resection showed no significant effect on survival, recurrence, or postoperative CSF leak. Oncologic outcomes may be comparable when resection is tailored to individual patient and tumor characteristics.
The combined impact of midlife and late‐life vascular risk factors on 33‐year incident dementia: the Atherosclerosis Risk in Communities Study
Palta, Priya, Windham, B. Gwen, Coresh, Josef, Sharrett, Richey, Gross, Alden L. , Smith, Jason R. , Pike, James Russell , Selvin, Elizabeth , Lutsey, Pamela L. , Knopman, David S. , Deal, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.084043 Get It

AbstractBackgroundMidlife vascular risk factors are associated with an increased risk of dementia. However, the overall contribution of modifiable vascular risk factors in midlife and late‐life to dementia remains unclear. In this study, we quantified population attributable fractions, which account for risk factor prevalence and strength of relative risks, of incident dementia from vascular risk factors measured in midlife and early late‐life.MethodWe used 33 years of prospective cohort data in the Atherosclerosis Risk in Communities Study. Incident dementia (community surveillance and algorithmic diagnosis with expert clinical adjudication) was ascertained from baseline (1987‐1989) through December 31, 2020. We quantified population attributable fractions of incident dementia by age 80 from the combination of hypertension (systolic blood pressure ≥130, diastolic blood pressure ≥80, or use of medication), diabetes (fasting glucose ≥126, non‐fasting glucose ≥200, self‐reported physician diagnosis of diabetes, or use of medication for diabetes/insulin), and self‐reported current cigarette smoking (at least one risk factor versus none) measured at different ages (45‐54 [n = 7,731], 55‐64 [n = 12,273]; 65‐74 [n = 6,660]). We also computed attributable fractions stratified by sex, apolipoprotein ε4 genotype, and self‐reported race.ResultThe prevalence of having one or more of the vascular risk factors was 61.6% (95% CI: 60.5, 62.7%) at age 45‐54 and increased to 77.5% (95% CI: 76.5, 78.5%) by age 65‐74. Population attributable fractions of dementia increased from 22.7% (95% CI: 15.3, 30.1%) for vascular risk factors measured at age 45‐54 to 45.4% (95% CI: 32.5, 58.3%) for vascular risk factors assessed at age 65‐74 (see Figure). Attributable fractions were larger in females, participants without apolipoprotein ε4 alleles, and Black participants (Figure).ConclusionBetween 23% to 45% of incident dementia cases by age 80 were attributed to a combination of hypertension, diabetes, or current smoking up through age 74. Attributable fractions for the combined impact of vascular risk varied by key demographics. Public health strategies targeting modifiable vascular risk factors could reduce dementia risk and increase healthy lifespan.
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma
Kshirsagar, Rijul S. , Harris, Jacob , Chang, Eugene H. , Fung, Nicholas , Hong, Michelle , Johnson, Brian J. , Kohanski, Michael A. , Lee, Jivianne T. , Nabavizadeh, Seyed Ali , Obermeyer, Isaac P. , Pandrangi, Vivek C. , Smith, Timothy L. , Wang, Marilene B. , Lazor, Jillian W. , Mitchell, Tara C. , Adappa, Nithin D. , Adappa, Nithin D. , Harris, Jacob , Lee, Jivianne T , Obermeyer, Isaac P , Smith, Timothy L , Snyderman, Carl H , Kuan, Edward C , Kshirsagar, Rijul S , Eide, Jacob G. , Abiri, Arash , Beswick, Daniel M. , Fung, Nicholas, Le, Christopher H. , Pinheiro‐Neto, Carlos , Suh, Jeffrey D. , Wang, Eric W , Choby, Garret , Geltzeiler, Mathew , Adappa, Nithin D.

Mayo Clinic

American Journal of Rhinology & Allergy | January 9, 2025 | Volume: 39 | Issue: 2 | Pages: 102-108

10.1177/19458924241308953 | PMID 39782303 Get It

Background Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( n = 17, 32.7%) or pembrolizumab ( n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
TGFBR2 High mesenchymal glioma stem cells phenocopy regulatory T cells to suppress CD4+ and CD8+ T cell function
Johnson, Amanda , Korleski, Jack , Smith-Connor, Karen, Laterra, John , Li, Yunqing , Johnson, Amanda L , Li, Yunqing , Khela, Harmon Singh , Sall, Sophie , Li, Yun-Qing , Zhou, Weiqiang , López-Bertoni, Hernando

Mayo Clinic

No container title available | January 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.07.631757 | PMID 39829747 Get It

Abstract Attempts to activate an anti-tumor immune response in glioblastoma (GBM) have been met with many challenges due to its inherently immunosuppressive tumor microenvironment. The degree and mechanisms by which molecularly and phenotypically diverse tumor-propagating glioma stem cells (GSCs) contribute to this state are poorly defined. In this study, our multifaceted approach combining bioinformatics analyses of clinical and experimental datasets, single-cell sequencing, and molecular and pharmacologic manipulation of patient-derived cells identified GSCs expressing immunosuppressive effectors mimicking regulatory T cells (Tregs). We show that this I mmunosuppressive T reg- L ike (ITL) GSC state is specific to the mesenchymal GSC subset and is associated with and driven specifically by TGF-β type II receptor (TGFBR2) in contrast to TGFBR1. Transgenic TGFBR2 expression in patient-derived GBM neurospheres promoted a mesenchymal transition and induced a 6-gene ITL signature consisting of CD274 (PD-L1), NT5E (CD73), ENTPD1 (CD39), LGALS1 (galectin-1), PDCD1LG2 (PD-L2), and TGFB1. This TGFBR2-driven ITL signature was identified in clinical GBM specimens, patient-derived GSCs and systemic mesenchymal malignancies. TGFBR2 High GSCs inhibited CD4+ and CD8+ T cell viability and their capacity to kill GBM cells, effects reversed by pharmacologic and shRNA-based TGFBR2 inhibition. Collectively, our data identify an immunosuppressive GSC state that is TGFBR2-dependent and susceptible to TGFBR2-targeted therapeutics.
Increased Mortality in Kidney Transplant Recipients During the Delta/Omicron Era of the COVID‐19 Pandemic Despite Widespread Vaccination
Smith, Byron H. , Nair, S. , Mai, Martin, Khamash, Hasan , Schinstock, Carrie A. , Liang, Yun , Abdelrheem, Ahmed, Park, Walter D. , Smith, Byron , Nair, Sumi, Wadei, Hani M , Schinstock, Carrie , Park, Walter , Badley, Andrew, Stegall, Mark D , Wadei, Hani M. , Liang, Yun, Badley, Andrew D. , Stegall, Mark D.

Mayo Clinic

Clinical Transplantation | January 7, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70071 | PMID 39777936 Get It

ABSTRACTIntroductionThe incidence of mortality late in the pandemic, particularly after widespread vaccine availability, is not well understood. Herein, we elucidate the effect of this impact of the COVID pandemic as well as risk factors for mortality during it.MethodsThe primary end point was death with a functioning graft with secondary endpoints of mortality rates in subgroups and at different time intervals during the pandemic.ResultsDespite widespread vaccination, mortality rates for kidney transplant (KTx) recipients almost doubled during the COVID‐19 era (6.40 deaths per 100 person years vs. 3.54 pre‐COVID). Mortality increased in all racial/ethnic groups but increased more in Native Americans, Hispanics, and African Americans compared to non‐Hispanic Caucasians. The highest mortality rate occurred during the Delta and Omicron time frames. In contrast to the general population, mortality was more evenly spread across age groups in KTx recipients.ConclusionsMortality rates during the COVID‐19 era were extremely high, more than doubling in some racial/ethnic groups. We conclude that the KTx population was a particularly vulnerable group during the COVID‐19 era and suggests the need for further research into the management of variants in the future.